The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Loxo/Lilly; Novartis; Roche/Genentech; TG Therapeutics
Consulting or Advisory Role - Ascentage Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Loxo/Lilly; Merck; Roche/Genentech (Inst); TG Therapeutics
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.
 
Catherine Callaghan Coombs
Stock and Other Ownership Interests - Bluebird Bio; CTI BioPharma Corp
Honoraria - Abbvie; AstraZeneca; BeiGene; Genentech; H3 Biomedicine; Janssen; LOXO; MEI Pharma; MingSight; Novartis; Octapharm; Pharmacyclics; TG Therapeutics
Consulting or Advisory Role - Abbvie; Genentech; Lilly
Speakers' Bureau - Abbvie; BeiGene; Genentech
Research Funding - Loxo (Inst)
 
Nirav Niranjan Shah
Stock and Other Ownership Interests - Tundra Targeted Therapeutics
Consulting or Advisory Role - Incyte; Janssen Oncology; Juno/Bristol-Myers Sqibb; Kite, a Gilead company; Loxo/Lilly; Novartis; Seagen; TG Therapeutics
Research Funding - Adaptive Biotechnologies; Loxo/Lilly; Miltenyi Biotec
Travel, Accommodations, Expenses - Miltenyi Biotec
 
Wojciech Jurczak
Consulting or Advisory Role - AstraZeneca; BeiGene; Roche
Research Funding - Acerta Pharma; BeiGene; Epizyme; Janssen-Cilag; MEI Pharma; Morphosys; Roche; Sandoz-Novartis; Takeda; TG Therapeutics; TG Therapeutics
 
Jennifer Ann Woyach
Consulting or Advisory Role - AstraZeneca; Beigene; Genentech; Janssen; Loxo; Newave Pharmaceutical; Pharmacyclics
Research Funding - Janssen; Karyopharm Therapeutics; MorphoSys; Schrodinger
 
Chan Cheah
No Relationships to Disclose
 
Krish Patel
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Epizyme; Genentech; Kite, a Gilead company; Loxo/Lilly; Morphosys; Pharmacyclics; Seagen; TG Therapeutics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Kite, a Gilead company; TG Therapeutics
Research Funding - Aptevo Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curis (Inst); Epizyme (Inst); Fate Therapeutics (Inst); Kite/Gilead (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Xencor (Inst)
 
Kami J. Maddocks
Honoraria - ADC Therapeutics; AstraZeneca/Merck; BeiGene; BMS; Celgene; Epizyme; Genentech; Genmab; Incyte; Karyopharm Therapeutics; Kite, a Gilead company; Lilly; MorphoSys; Pharmacyclics; Seagen
Research Funding - Bristol-Myers Squibb; Merck; Pharmacyclics
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - BeiGene (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Catherine E. Muehlenbein
Employment - Loxo@Lilly
Stock and Other Ownership Interests - Lilly O.
 
Chunxiao Wang
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
 
Sarang Abhyankar
Employment - Loxo@Lilly
Stock and Other Ownership Interests - Lilly O.
 
Donald Edward Tsai
Employment - Loxo@Lilly
Stock and Other Ownership Interests - Lilly O.
 
Toby A. Eyre
Honoraria - Abbvie; AstraZeneca; Gilead Sciences; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Gilead Sciences; Incyte; Kite, a Gilead Company; Loxo/Lilly; Roche; Secura Bio (I)
Speakers' Bureau - Abbvie; AstraZeneca; Incyte; Kite/Gilead; Loxo/Lilly; Medscape; Peerview; Roche
Research Funding - AstraZeneca; BeiGene
Other Relationship - Loxo/Lilly